Trader consensus prices "No" at 89% for a hantavirus vaccine approval in 2026, driven by the absence of any candidates in Phase 3 clinical trials, as confirmed by recent NIH and WHO reports amid a deadly Andes virus outbreak on a cruise ship reported May 6, 2026. Official sources like the CDC and WHO state no licensed vaccines exist for hantaviruses causing hantavirus pulmonary syndrome (HPS) or hemorrhagic fever with renal syndrome (HFRS), with pipeline efforts—such as DNA vaccines from USAMRIID and antigens from University of Bath researchers—limited to preclinical or early Phase 1 stages. Historical precedents show vaccine development timelines exceeding five years post-Phase 1 without accelerated funding like Operation Warp Speed, rendering FDA or EMA approval by year-end improbable despite heightened research interest. Upcoming Phase 1 initiations offer long-shot potential but underscore entrenched scientific and logistical hurdles.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$83,355 Vol.
$83,355 Vol.
Dec 31, 2026
$83,355 Vol.
$83,355 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus prices "No" at 89% for a hantavirus vaccine approval in 2026, driven by the absence of any candidates in Phase 3 clinical trials, as confirmed by recent NIH and WHO reports amid a deadly Andes virus outbreak on a cruise ship reported May 6, 2026. Official sources like the CDC and WHO state no licensed vaccines exist for hantaviruses causing hantavirus pulmonary syndrome (HPS) or hemorrhagic fever with renal syndrome (HFRS), with pipeline efforts—such as DNA vaccines from USAMRIID and antigens from University of Bath researchers—limited to preclinical or early Phase 1 stages. Historical precedents show vaccine development timelines exceeding five years post-Phase 1 without accelerated funding like Operation Warp Speed, rendering FDA or EMA approval by year-end improbable despite heightened research interest. Upcoming Phase 1 initiations offer long-shot potential but underscore entrenched scientific and logistical hurdles.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Binuksan ang Market: May 4, 2026, 10:39 AM ET
Volume
$83,355Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus prices "No" at 89% for a hantavirus vaccine approval in 2026, driven by the absence of any candidates in Phase 3 clinical trials, as confirmed by recent NIH and WHO reports amid a deadly Andes virus outbreak on a cruise ship reported May 6, 2026. Official sources like the CDC and WHO state no licensed vaccines exist for hantaviruses causing hantavirus pulmonary syndrome (HPS) or hemorrhagic fever with renal syndrome (HFRS), with pipeline efforts—such as DNA vaccines from USAMRIID and antigens from University of Bath researchers—limited to preclinical or early Phase 1 stages. Historical precedents show vaccine development timelines exceeding five years post-Phase 1 without accelerated funding like Operation Warp Speed, rendering FDA or EMA approval by year-end improbable despite heightened research interest. Upcoming Phase 1 initiations offer long-shot potential but underscore entrenched scientific and logistical hurdles.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$83,355Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus prices "No" at 89% for a hantavirus vaccine approval in 2026, driven by the absence of any candidates in Phase 3 clinical trials, as confirmed by recent NIH and WHO reports amid a deadly Andes virus outbreak on a cruise ship reported May 6, 2026. Official sources like the CDC and WHO state no licensed vaccines exist for hantaviruses causing hantavirus pulmonary syndrome (HPS) or hemorrhagic fever with renal syndrome (HFRS), with pipeline efforts—such as DNA vaccines from USAMRIID and antigens from University of Bath researchers—limited to preclinical or early Phase 1 stages. Historical precedents show vaccine development timelines exceeding five years post-Phase 1 without accelerated funding like Operation Warp Speed, rendering FDA or EMA approval by year-end improbable despite heightened research interest. Upcoming Phase 1 initiations offer long-shot potential but underscore entrenched scientific and logistical hurdles.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong